{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:00:40Z","timestamp":1790312440005,"version":"4.1.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Akita University Early-Career Researcher Support Program","id":[{"id":"https:\/\/ror.org\/03hv1ad10","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The 2022 revision of the Japanese Classification of Esophageal Cancer reclassified certain lymph node metastases previously considered locoregional as distant lymph node metastasis. Consequently, some patients previously diagnosed with stage IVA or III disease and treated with definitive chemoradiotherapy (dCRT) are now categorized as stage IVB disease with distant lymph node metastasis (IVB-Lym). We retrospectively evaluated the outcomes of dCRT in patients initially diagnosed with stage IVA or III disease and subsequently reclassified under the revised system. Among patients with esophageal cancer who underwent dCRT between January 2017 and December 2020 at our institution, 65 were reclassified as stage IVA (n\u2009=\u200919) or stage IVB-Lym (n\u2009=\u200946). Best overall response, overall survival (OS), progression-free survival (PFS) and chemotherapy-related adverse events (AEs) were evaluated. Complete or partial response was achieved in 84.2% of patients with stage IVA and 84.4% of those with stage IVB-Lym. The median OS and PFS were 26 and 8\u00a0months, respectively, in the stage IVA group and 35 and 9\u00a0months, respectively, in the stage IVB-Lym group. No significant differences were observed in OS (P\u2009=\u20090.69) or PFS (P\u2009=\u20090.67) between the two groups. The incidence and severity of AEs were generally comparable. No significant differences in efficacy or toxicity were observed between patients with reclassified stage IVB-Lym and those with stage IVA disease. These findings suggest that dCRT may be considered a treatment option for carefully selected patients with stage IVB-Lym following comprehensive clinical evaluation.<\/jats:p>","DOI":"10.1093\/jrr\/rrag083","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:12:22Z","timestamp":1788520342000},"source":"Crossref","is-referenced-by-count":0,"title":["Revision of lymph node classification in the Japanese Classification of Esophageal Cancer and its impact on definitive chemoradiotherapy for stage IV esophageal cancer: a single-institution retrospective study"],"prefix":"10.1093","author":[{"given":"Tetsugaku","family":"Shinozaki","sequence":"first","affiliation":[{"name":"Department of Radiology, Akita University Graduate School of Medicine , 1-1-1 Hondo, Akita 010-8543 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2013-7413","authenticated-orcid":false,"given":"Yuki","family":"Wada","sequence":"additional","affiliation":[{"name":"Department of Radiology, Akita University Graduate School of Medicine , 1-1-1 Hondo, Akita 010-8543 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0780-9157","authenticated-orcid":false,"given":"Satoshi","family":"Kumagai","sequence":"additional","affiliation":[{"name":"Department of Radiology, Akita University Graduate School of Medicine , 1-1-1 Hondo, Akita 010-8543 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasuku","family":"Kume","sequence":"additional","affiliation":[{"name":"Department of Radiology, Akita University Graduate School of Medicine , 1-1-1 Hondo, Akita 010-8543 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8570-5453","authenticated-orcid":false,"given":"Noriko","family":"Takagi","sequence":"additional","affiliation":[{"name":"Department of Radiology, Akita University Graduate School of Medicine , 1-1-1 Hondo, Akita 010-8543 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7301-1307","authenticated-orcid":false,"given":"Kenta","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Akita University Graduate School of Medicine , 1-1-1 Hondo, Akita 010-8543 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0229-4172","authenticated-orcid":false,"given":"Tamotsu","family":"Matsuhashi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Akita University Graduate School of Medicine , 1-1-1 Hondo, Akita 010-8543 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsunori","family":"Iijima","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Akita University Graduate School of Medicine , 1-1-1 Hondo, Akita 010-8543 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushi","family":"Nagaki","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Akita University Graduate School of Medicine , 1-1-1 Hondo, Akita 010-8543 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3446-6840","authenticated-orcid":false,"given":"Akiyuki","family":"Wakita","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Akita University Graduate School of Medicine , 1-1-1 Hondo, Akita 010-8543 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Akita University Graduate School of Medicine , 1-1-1 Hondo, Akita 010-8543 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8700-9731","authenticated-orcid":false,"given":"Naoko","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Radiology, Akita University Graduate School of Medicine , 1-1-1 Hondo, Akita 010-8543 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"key":"2026092500380440100_ref1","doi-asserted-by":"publisher","DOI":"10.1002\/9780471420194.tnmc26.pub3","volume-title":"TNM Classification of Malignant Tumours","author":"Brierley","year":"2017","edition":"eighth"},{"key":"2026092500380440100_ref2","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10388-024-01054-y","article-title":"Japanese classification of esophageal cancer, 12th edition: part I","volume":"21","author":"Mine","year":"2024","journal-title":"Esophagus"},{"key":"2026092500380440100_ref3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10388-016-0551-7","article-title":"Japanese classification of esophageal cancer, 11th edition: part I","volume":"14","author":"Japan Esophageal Society","year":"2017","journal-title":"Esophagus"},{"key":"2026092500380440100_ref4","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1007\/s10388-022-00977-8","article-title":"Significance of dissection in each regional lymph-node station of esophageal cancer based on efficacy index and recurrence patterns after curative esophagectomy","volume":"20","author":"Kanemura","year":"2023","journal-title":"Esophagus"},{"key":"2026092500380440100_ref5","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1245\/s10434-023-14562-5","article-title":"Significance of surgery for resectable M1 lymph node metastases without organ metastasis in esophageal carcinoma in the era of neoadjuvant treatment","volume":"31","author":"Igaue","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"2026092500380440100_ref6","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1097\/01.sla.0000118562.97742.29","article-title":"Improved survival for patients with upper and\/or middle mediastinal lymph node metastasis of squamous cell carcinoma of the lower thoracic esophagus treated with 3-field dissection","volume":"239","author":"Igaki","year":"2004","journal-title":"Ann Surg"},{"key":"2026092500380440100_ref7","doi-asserted-by":"publisher","first-page":"983","DOI":"10.3390\/cancers13050983","article-title":"Neoadjuvant chemoradiotherapy followed by esophagectomy with three-field lymph node dissection for thoracic esophageal squamous cell carcinoma patients with clinical stage III and with supraclavicular lymph node metastasis","volume":"13","author":"Sato","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026092500380440100_ref8","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1093\/jrr\/rraf029","article-title":"Radiotherapy treatment planning for esophageal cancer: JASTRO guidelines 2024 for radiotherapy treatment planning","volume":"66","author":"Jingu","year":"2025","journal-title":"J Radiat Res"},{"key":"2026092500380440100_ref9","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1007\/s11604-013-0180-1","article-title":"Outcomes of patients with stage IVA esophageal cancer (Japanese classification) treated with definitive chemoradiotherapy","volume":"31","author":"Anbai","year":"2013","journal-title":"Jpn J Radiol"},{"key":"2026092500380440100_ref10","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/cancers13010008","article-title":"Outcomes of definitive chemoradiotherapy for stage IVa (T4b vs. N4) esophageal squamous cell carcinoma based on the Japanese classification system: a retrospective single-center study","volume":"13","author":"Wada","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026092500380440100_ref11","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2026092500380440100_ref12","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0","author":"National Cancer Institute","year":"2017"},{"key":"2026092500380440100_ref13","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/cas.12622","article-title":"Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303)","volume":"106","author":"Shinoda","year":"2015","journal-title":"Cancer Sci"},{"key":"2026092500380440100_ref14","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s12029-025-01258-0","article-title":"Prognostic impact of thoracic extra-regional lymph node metastasis defined by the 12th Japanese classification following definitive radiotherapy for esophageal squamous cell carcinoma","volume":"56","author":"Inada","year":"2025","journal-title":"J Gastrointest Cancer"},{"key":"2026092500380440100_ref15","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1200\/JCO.1999.17.9.2915","article-title":"Definitive chemoradiotherapy for T4 and\/or M1 lymph node squamous cell carcinoma of the esophagus","volume":"17","author":"Ohtsu","year":"1999","journal-title":"J Clin Oncol"},{"key":"2026092500380440100_ref16","doi-asserted-by":"publisher","first-page":"100426","DOI":"10.1016\/j.jtocrr.2022.100426","article-title":"Nonregional lymph nodes as the only metastatic site in stage IV esophageal cancer","volume":"3","author":"Zhan","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"2026092500380440100_ref17","doi-asserted-by":"publisher","first-page":"doaf095","DOI":"10.1093\/dote\/doaf095","article-title":"Treatment outcomes of esophageal squamous cell carcinoma with cM1 lymph node without organ metastasis","volume":"38","author":"Ohsawa","year":"2025","journal-title":"Dis Esophagus"},{"key":"2026092500380440100_ref18","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s10388-023-00993-2","article-title":"Esophageal cancer practice guidelines 2022 edited by the Japan esophageal society: part 1","volume":"20","author":"Kitagawa","year":"2023","journal-title":"Esophagus"},{"key":"2026092500380440100_ref19","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa2111380","article-title":"Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma","volume":"386","author":"Doki","year":"2022","journal-title":"N Engl J Med"},{"key":"2026092500380440100_ref20","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet"},{"key":"2026092500380440100_ref21","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/S1470-2045(23)00108-0","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study","volume":"24","author":"Xu","year":"2023","journal-title":"Lancet Oncol"},{"key":"2026092500380440100_ref22","doi-asserted-by":"publisher","first-page":"171","DOI":"10.20892\/j.issn.2095-3941.2016.0015","article-title":"Immuno-oncology combinations: raising the tail of the survival curve","volume":"13","author":"Harris","year":"2016","journal-title":"Cancer Biol Med"},{"key":"2026092500380440100_ref23"},{"key":"2026092500380440100_ref24","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13014-016-0589-7","article-title":"Involved-field radiotherapy for esophageal squamous cell carcinoma: theory and practice","volume":"11","author":"Li","year":"2016","journal-title":"Radiat Oncol"}],"container-title":["Journal of Radiation Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jrr\/advance-article-pdf\/doi\/10.1093\/jrr\/rrag083\/71384428\/rrag083.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jrr\/advance-article-pdf\/doi\/10.1093\/jrr\/rrag083\/71384428\/rrag083.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:38:21Z","timestamp":1790311101000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jrr\/advance-article\/doi\/10.1093\/jrr\/rrag083\/8834129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":24,"URL":"https:\/\/doi.org\/10.1093\/jrr\/rrag083","relation":{},"ISSN":["0449-3060","1349-9157"],"issn-type":[{"value":"0449-3060","type":"print"},{"value":"1349-9157","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"article-number":"rrag083"}}